This activity is supported by an independent medical educational grant from Sandoz Inc., a Novartis Company.
Best Practices in the Management of Infectious Complications for Patients with Cancer
James S. Lewis II, PharmD, FIDSA
Oregon Health and Science University
Immune suppression increases the risk for developing infection and/or sepsis. As antibiotic resistant bacteria are becoming ubiquitous, managing infection becomes more complex. Optimizing preventive measures, early diagnosis and management of infection is of the highest priority in cancer care. This educational activity will enable advanced practitioners to hone their skills in risk assessment, recognition and early intervention in the management of infection, optimizing treatment in the era of antibiotic-resistant bacteria, and understand the role of biosimilars and their reference G-CSFs in the prophylaxis and treatment of febrile neutropenia.
These CE/CME/CEU accredited activities are jointly provided by